Anifrolumab, a relatively emerging monoclonal antigen, is creating considerable interest within the healthcare community as a potential therapy for various autoimmune conditions. This distinctive agent targets the IFN receptor alpha chain, effectively reducing inflammation that contributes to the pr

Tafasitamab, a monoclonal antibody, is receiving significant focus in oncology cancers , particularly diffuse large B-cell lymphoma . Its distinctive mechanism of function involves binding to CD19, a antigen present on B-cell membranes . Initially sanctioned for previously-treated diffuse large B-ce